7
Systemic Therapy
➤ 4.15: Concurrent administration of cisplatin with definitive radiation
therapy should be offered to patients without contraindications to
cisplatin chemotherapy and with a suspected mucosal primary HPV/
p16-negative squamous cell carcinoma in the presence of unresected
AJCC 8th N2-N3 nodal disease. (Strong recommendation; EB-B-H)
➤ 4.16: Concurrent administration of cisplatin with definitive radiation
therapy should be offered to patients without contraindications to
cisplatin chemotherapy and with a suspected mucosal primary HPV/
p16-positive squamous cell carcinoma in the presence of unresected
multiple ipsilateral, or bilateral lymph node involvement, or lymph
nodes >3 cm in size. (Strong recommendation; EB-B-H)
➤ 4.17: Concurrent administration of cisplatin to adjuvant radiation
should be offered to patients without contraindications to cisplatin
chemotherapy and with a suspected mucosal primary squamous cell
carcinoma and pathologic evidence of ENE. (Strong recommendation;
EB-B-H)
➤ 4.18: Concurrent administration of cisplatin with definitive radiation
therapy should be offered to patients without contraindications to
cisplatin chemotherapy and with an EBV encoded early RNA (EBER)
positive Stage II-IVA (AJCC 8th N2-N3) carcinoma of unknown
primary. (Strong recommendation; EB-B-H)
